Industry
Biotechnology
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Loading...
Open
8.28
Mkt cap
581M
Volume
598K
High
8.61
P/E Ratio
-4.53
52-wk high
16.65
Low
8.13
Div yield
N/A
52-wk low
6.33
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 7:42 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 1:29 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 5:33 pm
Portfolio Pulse from Benzinga Newsdesk
September 17, 2024 | 4:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.